Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for colorectal cancer: chemo-free combo targets tumors without harsh side effects

NCT ID NCT07257653

First seen Dec 04, 2025 · Last updated May 23, 2026 · Updated 26 times

Summary

This study tests whether a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without immunotherapy can control advanced colorectal cancer without traditional chemotherapy. About 70 adults with a specific genetic type (RAS/BRAF wild-type) will receive these drugs as their first treatment. The goal is to see if this approach can delay cancer growth and improve survival while reducing side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Zhejiang Province 310999

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.